TrialSignal transduction and targeted therapy2024

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Liping Dou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.